Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors

NCT00272740 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00272740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00272740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2000
Completion date
Not reported
Enrollment
93
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms